JP2017514924A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514924A5
JP2017514924A5 JP2017511153A JP2017511153A JP2017514924A5 JP 2017514924 A5 JP2017514924 A5 JP 2017514924A5 JP 2017511153 A JP2017511153 A JP 2017511153A JP 2017511153 A JP2017511153 A JP 2017511153A JP 2017514924 A5 JP2017514924 A5 JP 2017514924A5
Authority
JP
Japan
Prior art keywords
cyclophosphamide
containing composition
composition according
citric acid
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511153A
Other languages
English (en)
Japanese (ja)
Other versions
JP6516831B2 (ja
JP2017514924A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/028862 external-priority patent/WO2015171460A2/en
Publication of JP2017514924A publication Critical patent/JP2017514924A/ja
Publication of JP2017514924A5 publication Critical patent/JP2017514924A5/ja
Application granted granted Critical
Publication of JP6516831B2 publication Critical patent/JP6516831B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511153A 2014-05-09 2015-05-01 シクロホスファミド液状濃縮物の製剤 Expired - Fee Related JP6516831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461991247P 2014-05-09 2014-05-09
US61/991,247 2014-05-09
PCT/US2015/028862 WO2015171460A2 (en) 2014-05-09 2015-05-01 Formulations of cyclophosphamide liquid concentrate

Publications (3)

Publication Number Publication Date
JP2017514924A JP2017514924A (ja) 2017-06-08
JP2017514924A5 true JP2017514924A5 (enExample) 2018-04-26
JP6516831B2 JP6516831B2 (ja) 2019-05-22

Family

ID=54366856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511153A Expired - Fee Related JP6516831B2 (ja) 2014-05-09 2015-05-01 シクロホスファミド液状濃縮物の製剤

Country Status (10)

Country Link
US (3) US9662342B2 (enExample)
EP (1) EP3139929A4 (enExample)
JP (1) JP6516831B2 (enExample)
KR (1) KR20170008252A (enExample)
CN (1) CN106456654A (enExample)
AU (1) AU2015256331B2 (enExample)
BR (1) BR112016026140A2 (enExample)
CA (1) CA2948148C (enExample)
RU (1) RU2016147362A (enExample)
WO (1) WO2015171460A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
WO2016132270A1 (en) 2015-02-16 2016-08-25 Leiutis Pharmaceuticals Pvt Ltd Stable ready to use cyclophosphamide liquid formulations
US12453737B2 (en) 2018-08-03 2025-10-28 Sinotherapeutics Inc. Method for hydrating lyophilized cyclophosphamide composition and product thereof
WO2020178725A1 (en) * 2019-03-04 2020-09-10 Alembic Pharmaceuticals Limited Stable liquid composition of cyclophosphamide
BR112022000204A2 (pt) 2019-07-10 2022-02-22 Intas Pharmaceuticals Ltd Composição oral estável de ciclofosfamida, pó estável para solução oral, pó estável para solução oral na forma de um kit, e processo para preparação de um kit
WO2021009595A1 (en) * 2019-07-15 2021-01-21 Hetero Healthcare Limited Cyclophosphamide injectable composition and methods for producing same
US20230310468A1 (en) * 2020-08-17 2023-10-05 Sandoz Ag Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids
WO2023059885A1 (en) 2021-10-08 2023-04-13 Slayback Pharma Llc, Stable pharmaceutical compositions of cyclophosphamide
US11642358B1 (en) 2022-02-14 2023-05-09 Extrovis Ag Stable pharmaceutical formulation
US20240180935A1 (en) * 2022-11-22 2024-06-06 Navinta, Llc Solution formulation of cyclophosphamide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR75178E (enExample) 1956-12-20 1961-09-08
ES2038623T3 (es) * 1986-07-11 1993-08-01 Asta Medica Aktiengesellschaft Procedimiento para preparar soluciones de oxazafosforinas con estabilidad mejorada.
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
ATE348621T1 (de) * 1997-10-13 2007-01-15 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
AUPQ849900A0 (en) * 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
CN101039699B (zh) * 2004-10-15 2011-07-27 柳署弘 用于减小药物化合物毒性的方法和组合物
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
CN1923280A (zh) * 2005-08-30 2007-03-07 孔庆忠 一种含双氯乙胺类药物的抗癌缓释注射剂
JP5318403B2 (ja) * 2007-11-30 2013-10-16 株式会社Ｓｏｋｕｄｏ 基板処理装置
US8278220B2 (en) * 2008-08-08 2012-10-02 Fei Company Method to direct pattern metals on a substrate
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP2442789A1 (en) * 2009-06-18 2012-04-25 Abbott Laboratories Stable nanoparticulate drug suspension
US20140005148A1 (en) * 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards
WO2014068585A1 (en) * 2012-10-29 2014-05-08 Leiutis Pharmaceuticals Pvt. Ltd. Novel lyophilized compositions of cyclophosphamide

Similar Documents

Publication Publication Date Title
JP2017514924A5 (enExample)
RU2016147362A (ru) Препараты жидкого концетрата циклофосфамида
JP2015506989A5 (enExample)
EA201492021A1 (ru) Антительный состав
BR112017008660A2 (pt) formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
BR112014025564B8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma
BR112015012460B1 (pt) Formulação estabilizada de pemetrexede
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MX2021014029A (es) Formulaciones, fabricación y usos de imatinib.
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
WO2012071389A3 (en) Stable cannabinoid compositions and methods for making and storing them
CO6220902A2 (es) Formulacion en polvo del valganciclovir
JP2016503058A5 (enExample)
JP6094388B2 (ja) ペメトレキセドを含む注射用組成物
AR081870A1 (es) Composicion farmaceutica que comprende un derivado de amida o sal farmaceuticamente aceptable del mismo
PH12016502100A1 (en) Liquid formulation comprising gm-csf neutralizing compound
JP2017507973A5 (enExample)
HRP20171092T1 (hr) Stabilna tekuća formulacija amg 416 (velkalcetid)
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
PH12015500864A1 (en) Liquid formulation comprising gm-csf neutralizing compound
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
AR094770A1 (es) Composición masticable para administración oral y proceso para preparar la misma
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.